Sangamo Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Sangamo Therapeutics, Inc. (SGMO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-97.94-257.83-192.28-178.30-121.12-95.42-68.89
Depreciation & Amortization9.3622.1920.5620.4812.544.902.36
Deferred Income Tax0.00-6.340.000.000.000.000.00
Stock Based Compensation12.3827.3631.6532.9625.710.000.00
Change in Working Capital4.51-164.03-82.32-97.93249.47-75.1293.27
Change in Accounts Receivable0.402.762.34-0.7931.690.000.00
Change in Accounts Payable-14.175.5913.35-7.6610.700.000.00
Change in Other Working Capital4.29-7.49-6.67-6.50-6.350.000.00
Other Operating Activities0.33-5.2229.4022.1721.8817.040.97
Net Cash from Operating Activities-67.14-224.84-223.63-233.25169.88-144.4036.55
Investing Activities
Capital Expenditures-0.27-21.16-20.1723.2814.7120.68-43.07
Acquisitions1.950.000.00-0.12-0.70-0.26-75.65
Purchases of Investments35.84174.6979.46-338.16-256.210.000.00
Sales/Maturities of Investments35.84234.2479.46271.60-256.21-38.86-59.39
Net Cash from Investing Activities37.52153.5359.29248.20-271.63-59.80-178.11
Financing Activities
Common Stock Issued29.2816.0486.7627.10144.542.04215.76
Common Stock Repurchased-0.90-1.45-2.10-3.26-0.770.000.00
Other Financing Activities-0.90-1.45-2.10-3.26-0.77135.89-0.25
Net Cash from Financing Activities28.3814.5984.6632.86153.10142.03231.71
Summary
Effect of Forex Changes on Cash-2.051.481.25-0.26-0.450.180.44
Net Change in Cash-3.29-55.24-78.4347.8150.90-61.9990.15
Cash at Beginning of Period46.70101.94180.37132.8381.93143.9253.33
Cash at End of Period43.4246.70101.94132.8381.9381.93143.92
Free Cash Flow-67.41-246.00-243.80-256.53155.16-165.08-6.52